Form 4: Cytosorbents Corp: Chief Medical Officer Receives Stock Options Through Salary Reduction
SEC Form 4 Filing
Efthymios Deliargyris, Chief Medical Officer of Cytosorbents Corp, acquired 47,088 stock options as part of a voluntary salary reduction program.
Summary
- Efthymios Deliargyris, the Chief Medical Officer of Cytosorbents Corp, filed a Form 4 detailing changes in beneficial ownership.
- On March 29, 2024, Deliargyris acquired 47,088 stock options with an exercise price of $0.95.
- These options were granted as part of a voluntary salary reduction program for the period from April 1, 2024, to December 31, 2024.
- The stock options will vest fully on January 31, 2025, contingent upon continued service.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, suggesting a stable and incentivized management structure. The voluntary salary reduction is a positive sign of commitment.
Positives
- The acquisition of stock options by the Chief Medical Officer aligns his interests with those of the shareholders.
- The voluntary salary reduction demonstrates a commitment to the company's financial well-being.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value.
Comparison to Industry Standards
- Stock option grants are a typical component of executive compensation packages in the biotech industry.
- Companies like Amgen, Gilead, and Regeneron also utilize stock options to incentivize their executives.
- The vesting schedule and exercise price are generally aligned with industry norms to encourage long-term performance.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive incentive for the Chief Medical Officer.
- Employees may see the voluntary salary reduction as a sign of shared sacrifice and commitment to the company's success.
Key Dates
| Date | Description |
|---|---|
| 03/29/2024 | Date of transaction: Acquisition of 47,088 stock options. |
| 04/01/2024 | Start date of the voluntary salary reduction program. |
| 12/31/2024 | End date of the voluntary salary reduction program. |
| 01/31/2025 | Vesting date for the stock options, contingent upon continued service. |
| 03/29/2034 | Expiration date of the stock options. |
| 04/02/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.